SARCOMATRIX THERAPEUTICS CORP.
FOR IMMEDIATE RELEASE
Sarcomatrix Applies SarcoVista™ Translational Modeling to First-in-Human Dose Selection for S-969
The preclinical-stage company is using its proprietary modeling platform to inform the starting dose and escalation design for the planned Phase 1 study of its oral, mutation-agnostic candidate for Duchenne muscular dystrophy.
RENO, Nev., July 27, 2026 : Sarcomatrix Therapeutics Corp., a Delaware corporation, today described the role of SarcoVista™, its proprietary translational modeling platform, in selecting the starting dose and escalation design for the planned first-in-human study of S-969, an investigational oral, once-daily small molecule in development for Duchenne muscular dystrophy and related muscle-wasting conditions.
Sarcomatrix is a preclinical-stage company. S-969 has not been administered to humans and has not been approved by any regulatory authority for any use.
The decision that has to be made without human data
Choosing the first dose given to a human being is among the highest-consequence decisions in drug development, and by definition it has to be made before any human has been dosed.
The consequences run in both directions. Set the starting dose too low and a study spends months and cohorts climbing toward any biologically meaningful exposure, consuming time and capital that a rare disease program does not have to spare. Set it too high and the study carries risk that could have been avoided. The decision rests entirely on what laboratory and animal data can be made to say about a species those studies did not measure.
What SarcoVista integrates
SarcoVista integrates Sarcomatrix's own cross-species datasets, spanning human muscle cell work, rodent studies, large-animal studies, and non-human primate pharmacology, into models used to inform dose selection, cohort structure, and endpoint strategy for the planned study.
The underlying data reflects two decades of muscle-specific research originating in the laboratory of Dean Burkin, PhD, at the University of Nevada, Reno, together with the company's own program work. SarcoVista is a distinct asset from the S-969 and LAM-111 programs and is applied across both.
What modeling does, and what it does not do
Modeling informs a decision. It does not predict an outcome.
No model substitutes for a clinical trial. The behavior of S-969 in humans is unknown, will be established only through clinical study, and may differ materially from what any model anticipates. The company is not reporting dose levels, exposure targets, or safety margins, and nothing in this release should be read as a characterization of the safety, tolerability, or activity of S-969.
Program context
S-969 is an oral, once-daily investigational small molecule directed at alpha-7 beta-1 integrin, a protein that serves both as a structural anchor holding the muscle fiber membrane to surrounding tissue and as a signaling node supporting the muscle's own regenerative program. Because the approach does not depend on correcting any individual genetic error, it is in development across Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophy type 2I/R9.
The company's second program, LAM-111, a recombinant laminin-111 protein for LAMA2-related congenital muscular dystrophy, holds Orphan Drug Designation in both the United States and the European Union. An orphan drug application for S-969 is in progress and designation has not been granted.
Both programs are held under a worldwide exclusive license through the Nevada Research and Innovation Corporation, the technology commercialization affiliate of the University of Nevada, Reno.
Sarcomatrix has stated that it expects to begin first-in-human dosing in 2027. Development timelines at this stage commonly move, and no assurance can be given that any future milestone will be met.
|
“The starting dose is a decision you make once, without any human data, and every cohort that follows inherits it. SarcoVista lets us make that decision against everything we have learned across species over twenty years rather than against a single study.” Ryan Wuebbles, PhD, Co-Founder and Chief Scientific Officer, Sarcomatrix Therapeutics Corp. |
Investor information
Sarcomatrix's Regulation D, Rule 506(c) round is open to verified accredited investors at sarcomatrix.com/investors, on the KoreConX platform with KoreTransfer USA LLC as transfer agent. Under Rule 506(c), self-certification alone is not sufficient. Verification runs through the offering platform, and complete terms and risk disclosures follow there once verification is complete. The round closes September 30, 2026, subject to earlier closing if fully subscribed or extension at the company's discretion.
Understand the risks
Sarcomatrix has no approved products and no product revenue, and its candidates have never been tested in humans. Most experimental drugs fail. There is no public market for these shares and none is expected. Development timelines commonly slip. An investor could lose the entire amount invested, which is a realistic outcome in early-stage biotechnology. Only invest what you can afford to lose entirely.
About Sarcomatrix Therapeutics Corp.
Sarcomatrix Therapeutics Corp., a Delaware corporation headquartered in Reno, Nevada, is a preclinical-stage company developing novel, first-in-class treatments for rare muscle-wasting diseases including Duchenne muscular dystrophy, Becker muscular dystrophy, LGMD2I/R9, and LAMA2-related congenital muscular dystrophy. sarcomatrix.com
SarcoVista™ is a trademark of Sarcomatrix Therapeutics Corp.
Investor and media contact
Ray Jordan
President, Investor Relations
Putnam Insights
Forward-looking statements
This release contains forward-looking statements, including statements regarding development plans, modeling and dose selection activities, anticipated timelines, regulatory strategy, and potential therapeutic applications. These involve significant risks and uncertainties inherent in drug development, regulatory review, and financing, and actual results may differ materially. Product candidates are investigational and have not been approved by any regulatory authority. Laboratory and animal results are not necessarily predictive of results in humans, and modeling is not predictive of clinical outcome. Forward-looking statements speak only as of the date made, and the company undertakes no obligation to update them except as required by law. Sarcomatrix Therapeutics Corp. is not a reporting company under the Securities Exchange Act of 1934, and the statutory safe harbors for forward-looking statements are not available to it.
Offering disclaimer
This communication is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities. Any offer or sale is made solely pursuant to Rule 506(c) of Regulation D under the Securities Act of 1933, as amended, and only to persons whose accredited investor status has been verified. The securities are not registered under the Securities Act or any state securities laws and are offered in reliance on exemptions from registration. No securities regulator has approved this offering or passed upon the accuracy of any offering materials. Investment in an early-stage, preclinical biotechnology company involves a high degree of risk, including possible loss of the entire investment, and there is no public market for these securities. Prospective investors should review the offering materials and consult their own legal, tax, and financial advisors.
###
